Doses - CYTARABINE

For more information, refer to the protocol references found in the appendix or otherprotocols found in numerous references, including: Handbook of Small Animal Practice (Stann1988a); Handbook of Small Animal Therapeutics (Rosenthal 1985); and Textbook of Veterinary
Internal Medicine, 3rd Edition (Couto 1989a).

Dogs:

For susceptible neoplastic diseases:
a) 100 mg/m2 IV or SQ once daily for 2-4 days; repeat prn 20 mg/m2 intrathecally for 1-5days. (Thompson 1989a)
b) 100 mg/m2 IV (slowly), IM, or SQ once daily for 4 days, if no toxicity develops mayincrease dose by 50%. (Coppoc 1988)

Cats:

For susceptible neoplastic diseases:
a) 100 mg/m2 IV or SQ once daily for 2-4 days; repeat prn 20 mg/m2 intrathecally for 1-5 days. (Thompson 1989a)
b) 100 mg/m2 once daily for 2 days; 10 mg/m2 once daily for 2 weeks. (Couto 1989b)
Monitoring Parameters -

1) Efficacy; see the Protocol section or refer to the references from the Dosage section above for more information.

2) Toxicity; see Adverse Effects above. Regular hemograms are mandatory. Periodic liver and kidney function tests are suggested.
Client Information - Clients must be briefed on the possibilities of severe toxicity developingfrom this drug, including drug-related mortality. Clients should contact the veterinarian should thepatient exhibit any symptoms of profound depression, abnormal bleeding and/or bruising.
Dosage Forms/Preparations/FDA Approval Status/Withholding Times - Veterinary-Approved Products: None

Human-Approved Products:

Cytarabine Powder for Injection 100 mg, 500 mg, 1 g & 2 g in vials; Cytosar-U® (Upjohn) (Rx); generic (Rx)
Cytarabine Injection 20 mg/ml in 5 ml vials and 50 ml bulk vials; Tarabine PRS® (Adria) (Rx)